India’s Cadila Takes Saroglitazar Into NASH
This article was originally published in PharmAsia News
The Indian drug maker Zydus Cadila is working to treat NASH, the serious fatty liver disease, with its established diabetes dyslipidemia compound saroglitazar, which gained approval in India in 2013.
You may also be interested in...
Cirius Suspects Insulin Resistance Is Underlying Key To NASH
The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.
Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.